NASDAQ:KMDA - Kamada Stock Price, Price Target & More

$4.55 -0.05 (-1.09 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$4.60
Today's Range$4.55 - $4.65
52-Week Range$3.75 - $8.61
Volume17,634 shs
Average Volume21,674 shs
Market Capitalization$187.22 million
P/E Ratio25.28
Dividend YieldN/A
Beta1.18

About Kamada (NASDAQ:KMDA)

Kamada logoKamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472

Debt

Debt-to-Equity Ratio0.02%
Current Ratio3.30%
Quick Ratio2.58%

Price-To-Earnings

Trailing P/E Ratio25.28
Forward P/E Ratio21.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$102.82 million
Price / Sales1.78
Cash Flow$0.2528 per share
Price / Cash18.00
Book Value$2.22 per share
Price / Book2.05

Profitability

EPS (Most Recent Fiscal Year)$0.18
Net Income$6.90 million
Net Margins6.71%
Return on Equity9.06%
Return on Assets6.46%

Miscellaneous

Employees377
Outstanding Shares40,260,000

How to Become a New Pot Stock Millionaire

Kamada (NASDAQ:KMDA) Frequently Asked Questions

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How were Kamada's earnings last quarter?

Kamada Ltd (NASDAQ:KMDA) posted its quarterly earnings results on Wednesday, February, 7th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.10. The biotechnology company earned $35.71 million during the quarter, compared to the consensus estimate of $32.90 million. Kamada had a return on equity of 9.06% and a net margin of 6.71%. View Kamada's Earnings History.

When is Kamada's next earnings date?

Kamada is scheduled to release their next quarterly earnings announcement on Tuesday, May, 15th 2018. View Earnings Estimates for Kamada.

What price target have analysts set for KMDA?

3 analysts have issued 12 month price objectives for Kamada's shares. Their predictions range from $7.00 to $7.00. On average, they expect Kamada's share price to reach $7.00 in the next twelve months. View Analyst Ratings for Kamada.

Who are some of Kamada's key competitors?

Who are Kamada's key executives?

Kamada's management team includes the folowing people:
  • Leon Yehuda Recanati, Chairman of the Board (Age 67)
  • Amir London, Chief Executive Officer (Age 46)
  • David Tsur, Deputy Chairman of the Board (Age 67)
  • Chaime Orlev, Chief Financial Officer (Age 46)
  • Ruth Wolfson, Senior Vice President - Scientific Affairs (Age 69)
  • Barak Bashari, Vice President - Operations (Age 51)
  • Shani Dotan, Vice President - Human Resources (Age 42)
  • Yael Brenner, Vice President - Quality (Age 52)
  • Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D (Age 50)
  • Eran Schenker, Vice President - Medical Director (Age 53)

Has Kamada been receiving favorable news coverage?

Headlines about KMDA stock have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kamada earned a media sentiment score of 0.10 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $4.55.

How big of a company is Kamada?

Kamada has a market capitalization of $187.22 million and generates $102.82 million in revenue each year. The biotechnology company earns $6.90 million in net income (profit) each year or $0.18 on an earnings per share basis. Kamada employs 377 workers across the globe.

How can I contact Kamada?

Kamada's mailing address is 7 SAPIR STREET KIRYAT WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7414002. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]


MarketBeat Community Rating for Kamada (KMDA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  286
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kamada (NASDAQ:KMDA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Kamada in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 53.85%. The high price target for KMDA is $7.00 and the low price target for KMDA is $7.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$8.50$8.50
Price Target Upside: 53.85% upside35.92% upside75.26% upside75.26% upside

Kamada (NASDAQ:KMDA) Consensus Price Target History

Price Target History for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018HC WainwrightReiterated RatingBuyHighView Rating Details
2/2/2018Chardan CapitalInitiated CoverageBuy -> Buy$7.00LowView Rating Details
10/12/2017Jefferies GroupReiterated RatingBuy$7.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Kamada (NASDAQ:KMDA) Earnings History and Estimates Chart

Earnings by Quarter for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA) Earnings Estimates

2018 EPS Consensus Estimate: $0.22
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.02$0.02$0.02
Q2 20181$0.06$0.06$0.06
Q3 20181$0.05$0.05$0.05
Q4 20181$0.09$0.09$0.09

Kamada (NASDAQ KMDA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2018        
2/7/2018n/a$0.06$0.16$32.90 million$35.71 millionViewN/AView Earnings Details
11/13/2017Q3 2017($0.01)$24.84 million$22.92 millionViewN/AView Earnings Details
8/1/20176/30/2017$0.12$0.13$33.30 million$32.55 millionViewListenView Earnings Details
5/16/20173/31/2017($0.03)($0.11)$20.82 million$11.65 millionViewN/AView Earnings Details
2/6/201712/31/2016($0.04)($0.05)$27.74 million$24.26 millionViewListenView Earnings Details
11/10/20169/30/2016($0.04)($0.03)$20.32 million$19.37 millionViewN/AView Earnings Details
8/2/2016Q216($0.04)($0.04)$18.50 million$19.10 millionViewN/AView Earnings Details
5/9/2016Q1 2016($0.06)($0.06)$15.10 million$14.80 millionViewN/AView Earnings Details
2/2/2016Q415($0.09)$0.03$27.10 million$25.90 millionViewN/AView Earnings Details
11/10/2015Q315($0.04)($0.13)$18.67 million$16.10 millionViewListenView Earnings Details
7/30/2015Q215($0.03)($0.06)$21.82 million$19.20 millionViewListenView Earnings Details
5/12/2015Q115($0.05)($0.15)$16.12 million$9.00 millionViewListenView Earnings Details
2/11/2015Q4$0.01$0.05$24.53 million$25.79 millionViewN/AView Earnings Details
11/12/2014Q314($0.04)($0.09)$19.00 million$17.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.23)$17.17 million$15.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.03)($0.09)$15.97 million$13.20 millionViewN/AView Earnings Details
2/5/2014Q413$0.05$0.04$25.22 million$24.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.01$0.03$16.30 million$16.12 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.03)($0.07)$12.60 millionViewN/AView Earnings Details
3/9/2013Q4 2012($0.03)$0.11ViewN/AView Earnings Details
2/28/2012Q4 2011($0.03)($0.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Kamada (NASDAQ:KMDA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Kamada (NASDAQ KMDA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 9.14%
Insider Trading History for Kamada (NASDAQ:KMDA)
Insider Trading History for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ KMDA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Kamada (NASDAQ KMDA) News Headlines

Source:
DateHeadline
Kamada Ltd (KMDA) Given Average Rating of "Buy" by AnalystsKamada Ltd (KMDA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 18 at 9:03 AM
Zacks Investment Research Lowers Kamada (KMDA) to SellZacks Investment Research Lowers Kamada (KMDA) to Sell
www.americanbankingnews.com - April 17 at 9:49 PM
Kamada (KMDA) Downgraded to D+ at TheStreetKamada (KMDA) Downgraded to D+ at TheStreet
www.americanbankingnews.com - April 13 at 7:51 PM
Kamada (KMDA) Lowered to "Sell" at Zacks Investment ResearchKamada (KMDA) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 13 at 1:35 PM
Kamada (KMDA) Stock Rating Upgraded by Zacks Investment ResearchKamada (KMDA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:10 PM
Zacks Investment Research Downgrades Kamada (KMDA) to SellZacks Investment Research Downgrades Kamada (KMDA) to Sell
www.americanbankingnews.com - April 7 at 7:46 PM
$24.89 Million in Sales Expected for Kamada Ltd (KMDA) This Quarter$24.89 Million in Sales Expected for Kamada Ltd (KMDA) This Quarter
www.americanbankingnews.com - April 7 at 4:23 AM
$0.03 EPS Expected for Kamada Ltd (KMDA) This Quarter$0.03 EPS Expected for Kamada Ltd (KMDA) This Quarter
www.americanbankingnews.com - April 5 at 10:10 AM
Kamada Ltd (KMDA) Receives Average Rating of "Buy" from AnalystsKamada Ltd (KMDA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 24 at 8:28 AM
Kamada Ltd (KMDA) Expected to Post Quarterly Sales of $24.89 MillionKamada Ltd (KMDA) Expected to Post Quarterly Sales of $24.89 Million
www.americanbankingnews.com - March 21 at 5:56 AM
Kamada (KMDA) Stock Rating Upgraded by ValuEngineKamada (KMDA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 19 at 11:16 PM
Zacks: Analysts Expect Kamada Ltd (KMDA) to Announce $0.03 Earnings Per ShareZacks: Analysts Expect Kamada Ltd (KMDA) to Announce $0.03 Earnings Per Share
www.americanbankingnews.com - March 19 at 5:12 AM
Kamada (KMDA) Upgraded at ValuEngineKamada (KMDA) Upgraded at ValuEngine
www.americanbankingnews.com - March 18 at 10:28 PM
Kamada (KMDA) Cut to Sell at ValuEngineKamada (KMDA) Cut to Sell at ValuEngine
www.americanbankingnews.com - March 18 at 7:42 PM
Kamada (KMDA) Lowered to "Sell" at ValuEngineKamada (KMDA) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - March 4 at 3:54 PM
Zacks: Analysts Anticipate Kamada Ltd (KMDA) to Announce $0.03 Earnings Per ShareZacks: Analysts Anticipate Kamada Ltd (KMDA) to Announce $0.03 Earnings Per Share
www.americanbankingnews.com - March 2 at 5:12 AM
Kamada Ltd (KMDA) Receives Consensus Rating of "Buy" from AnalystsKamada Ltd (KMDA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 27 at 10:12 AM
Kamada (KMDA) Upgraded at TheStreetKamada (KMDA) Upgraded at TheStreet
www.americanbankingnews.com - February 18 at 9:22 PM
Zacks: Brokerages Anticipate Kamada Ltd (KMDA) to Post $0.03 Earnings Per ShareZacks: Brokerages Anticipate Kamada Ltd (KMDA) to Post $0.03 Earnings Per Share
www.americanbankingnews.com - February 13 at 11:14 AM
Jefferies Group Weighs in on Kamada Ltds Q1 2018 Earnings (KMDA)Jefferies Group Weighs in on Kamada Ltd's Q1 2018 Earnings (KMDA)
www.americanbankingnews.com - February 12 at 2:20 AM
Kamada (KMDA) Rating Increased to Hold at Zacks Investment ResearchKamada (KMDA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 11 at 9:36 AM
Research Analysts Offer Predictions for Kamada Ltds Q3 2018 Earnings (KMDA)Research Analysts Offer Predictions for Kamada Ltd's Q3 2018 Earnings (KMDA)
www.americanbankingnews.com - February 9 at 11:37 AM
Kamada (KMDA) Upgraded to "Hold" at ValuEngineKamada (KMDA) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 8 at 10:34 PM
Kamada (KMDA) Announces  Earnings ResultsKamada (KMDA) Announces Earnings Results
www.americanbankingnews.com - February 8 at 10:32 AM
Kamada posts 4Q profitKamada posts 4Q profit
finance.yahoo.com - February 8 at 8:49 AM
Kamada (KMDA) Rating Reiterated by HC WainwrightKamada (KMDA) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - February 8 at 7:50 AM
Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017
finance.yahoo.com - February 7 at 9:20 AM
Kamada (KMDA) Scheduled to Post Earnings on WednesdayKamada (KMDA) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - February 5 at 8:32 PM
Kamada (KMDA) versus Chiasma (CHMA) Financial SurveyKamada (KMDA) versus Chiasma (CHMA) Financial Survey
www.americanbankingnews.com - February 2 at 3:38 PM
Kamada (KMDA) Receives New Coverage from Analysts at Chardan CapitalKamada (KMDA) Receives New Coverage from Analysts at Chardan Capital
www.americanbankingnews.com - February 2 at 2:33 PM
Kamada Ltd (KMDA) Receives Consensus Rating of "Hold" from AnalystsKamada Ltd (KMDA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 2 at 9:48 AM
Kamada to Announce Fiscal Year 2017 Financial Results and Host Conference Call on February 7Kamada to Announce Fiscal Year 2017 Financial Results and Host Conference Call on February 7
finance.yahoo.com - February 2 at 9:17 AM
Zacks: Kamada Ltd (KMDA) Given $8.50 Consensus Target Price by BrokeragesZacks: Kamada Ltd (KMDA) Given $8.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - January 17 at 12:04 PM
Analyzing ChemoCentryx (CCXI) & Kamada (KMDA)Analyzing ChemoCentryx (CCXI) & Kamada (KMDA)
www.americanbankingnews.com - January 15 at 11:16 PM
Contrasting Kamada (KMDA) and Biogen (BIIB)Contrasting Kamada (KMDA) and Biogen (BIIB)
www.americanbankingnews.com - January 15 at 9:06 AM
Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant RejectionKamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
finance.yahoo.com - January 8 at 10:20 AM
Kamada (KMDA) Raised to "Hold" at ValuEngineKamada (KMDA) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - January 5 at 11:22 PM
Kamada (KMDA) & Cesca Therapeutics (KOOL) Critical AnalysisKamada (KMDA) & Cesca Therapeutics (KOOL) Critical Analysis
www.americanbankingnews.com - January 5 at 5:34 PM
Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host DiseaseKamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease
finance.yahoo.com - January 4 at 10:06 AM
 Kamada Ltd (KMDA) Given Consensus Recommendation of "Strong Buy" by Brokerages Kamada Ltd (KMDA) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 31 at 1:28 PM
ETFs with exposure to Kamada Ltd. : December 28, 2017ETFs with exposure to Kamada Ltd. : December 28, 2017
finance.yahoo.com - December 28 at 4:42 PM
 Kamada Ltd (KMDA) Given $8.50 Average Target Price by Brokerages Kamada Ltd (KMDA) Given $8.50 Average Target Price by Brokerages
www.americanbankingnews.com - December 22 at 5:23 PM
Comparing Kamada (KMDA) & Opiant Pharmaceuticals (OPNT)Comparing Kamada (KMDA) & Opiant Pharmaceuticals (OPNT)
www.americanbankingnews.com - December 17 at 1:28 PM
ETFs with exposure to Kamada Ltd. : December 12, 2017ETFs with exposure to Kamada Ltd. : December 12, 2017
finance.yahoo.com - December 12 at 5:02 PM
ETFs with exposure to Kamada Ltd. : December 1, 2017ETFs with exposure to Kamada Ltd. : December 1, 2017
finance.yahoo.com - December 1 at 5:29 PM
Kamada Ltd. :KMDA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017Kamada Ltd. :KMDA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 10:47 AM
 Kamada Ltd. (KMDA) Given Average Rating of "Strong Buy" by Analysts Kamada Ltd. (KMDA) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - November 27 at 11:26 AM
Kamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies InfectionKamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies Infection
finance.yahoo.com - November 22 at 1:38 AM
 Kamada Ltd. (KMDA) Given $8.50 Average Target Price by Brokerages Kamada Ltd. (KMDA) Given $8.50 Average Target Price by Brokerages
www.americanbankingnews.com - November 21 at 5:50 PM
Critical Review: Argos Therapeutics (ARGS) vs. Kamada (KMDA)Critical Review: Argos Therapeutics (ARGS) vs. Kamada (KMDA)
www.americanbankingnews.com - November 21 at 5:12 AM

SEC Filings

Kamada (NASDAQ:KMDA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kamada (NASDAQ:KMDA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kamada (NASDAQ KMDA) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.